Scott North
YOU?
Author Swipe
View article: Cohort Profile: Our Future Health
Cohort Profile: Our Future Health Open
View article: 76eP Clinical-grade comprehensive genomic profiling (CGP) of urothelial carcinoma (UC)
76eP Clinical-grade comprehensive genomic profiling (CGP) of urothelial carcinoma (UC) Open
View article: 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update)
2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update) Open
View article: Multicenter examination of contemporary penile prosthesis surgery infection prophylaxis practices
Multicenter examination of contemporary penile prosthesis surgery infection prophylaxis practices Open
View article: Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304) Open
What is this summary about? ENZAMET is a large international clinical trial involving people with metastatic hormone sensitive prostate cancer (mHSPC). Prior to the trial, standard treatment included testosterone suppression and sometimes,…
View article: 2024 CUA-GUMOC Expert Report: Management of unresectable locally advanced and metastatic urothelial carcinoma
2024 CUA-GUMOC Expert Report: Management of unresectable locally advanced and metastatic urothelial carcinoma Open
View article: Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer
Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer Open
Background: The management of advanced prostate cancer continues to evolve rapidly, particularly with the earlier use of survival-prolonging therapies in metastatic castration-sensitive prostate cancer (mCSPC). Though approved prior to the…
View article: Perioperative Blood Transfusion Is Associated with Worse Survival in Patients Undergoing Radical Cystectomy after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
Perioperative Blood Transfusion Is Associated with Worse Survival in Patients Undergoing Radical Cystectomy after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Open
Objectives: Perioperative blood transfusion (PBT) has been associated with worse survival after radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC). Here, we evaluated the association between PBT and survival aft…
View article: Table of Contents
Table of Contents Open
View article: High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors
High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors Open
Introduction: High-dose chemotherapy with autologous stem-cell transplantation (HDC-ASCT) is standard therapy for metastatic germ cell tumors (mGCTs) in patients whose disease progresses during or after conventional chemotherapy. We conduc…
View article: The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy
The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomy Open
INTRODUCTION: Cisplatin-based neoadjuvant chemotherapy (NAC) is the standard of care for patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC). Cisplatin, however, can induce renal toxicity. Furthermore, RC…
View article: 1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304) Open
View article: 1799P Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi)
1799P Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi) Open
View article: The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey Open
Background: Although metastatic germ cell tumor (GCT) is highly curable with initial cisplatin-based chemotherapy (CT), 20–30% of patients relapse. Salvage CT options include conventional (CDCT) and high dose chemotherapy (HDCT), however d…
View article: The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey Open
Background: Although metastatic GCT is highly curable with initial cisplatin-based chemotherapy (CT), 20-30% of patients relapse. Salvage CT options include conventional (CDCT) and high dose chemotherapy (HDCT), however definitive comparat…
View article: Supplementary Methods from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Supplementary Methods from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer Open
Methods for blood processing and DNA isolation.
View article: Data from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Data from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer Open
Purpose: Targeted agents and immunotherapies promise to transform the treatment of metastatic bladder cancer, but therapy selection will depend on practical tumor molecular stratification. Circulating tumor DNA (ctDNA) is establishe…
View article: Supplementary Methods from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Supplementary Methods from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer Open
Methods for blood processing and DNA isolation.
View article: Supplementary Figures from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Supplementary Figures from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer Open
File containing all 13 supplementary figures, complete with figure legends.
View article: Table S1 to S5 from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Table S1 to S5 from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer Open
Excel file with all five supplemental tables, each contained on a separate tab. Table S1 describes the patient cohort and clinical characteristics. Table S2 describes the targets of our custom sequencing approach. Table S3 relates cfDNA yi…
View article: Data from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Data from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer Open
Purpose: Targeted agents and immunotherapies promise to transform the treatment of metastatic bladder cancer, but therapy selection will depend on practical tumor molecular stratification. Circulating tumor DNA (ctDNA) is establishe…
View article: Supplementary Figures from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Supplementary Figures from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer Open
File containing all 13 supplementary figures, complete with figure legends.
View article: Table S1 to S5 from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Table S1 to S5 from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer Open
Excel file with all five supplemental tables, each contained on a separate tab. Table S1 describes the patient cohort and clinical characteristics. Table S2 describes the targets of our custom sequencing approach. Table S3 relates cfDNA yi…
View article: 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)
2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) Open
recommendation is represented by the words STRONG or WEAK.
View article: Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer
Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer Open
View article: Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study
Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study Open
We observed signs of TGCT stage migration during the COVID-19 pandemic, driven by a decline in stage II disease and a potential rise in stage III disease. Management of TGCTs should remain a priority, even during a global pandemic.
View article: Canadian Urological Association consensus guideline: Management of testicular germ cell cancer
Canadian Urological Association consensus guideline: Management of testicular germ cell cancer Open
At the Canadian GCT meeting held in Toronto in 2018, Canadian GCT providers
View article: Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada
Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada Open
There are no direct comparisons of the relative cost-effectiveness of second-generation anti-androgens (enzalutamide and apalutamide) used in managing metastatic castration-sensitive prostate cancer (mCSPC) in Canada. This study compared t…
View article: Corrigendum to “Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium” [Eur Urol Focus 2021;7:1347–54]
Corrigendum to “Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium” [Eur Urol Focus 2021;7:1347–54] Open
In the original article, the name of author Sia Daneshmand was incorrectly abbreviated as D. Daneshmand. The correct version is given in the above author list. Conflicts of interest: The authors have nothing to disclose.
View article: The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy
The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy Open
Background: In metastatic urothelial cancer (mUC), bone metastasis (BM) are associated with significant morbidity and mortality, yet their role as an independent prognostic variable remains unclear. We aimed to determine the impact of BM o…